- Markets
- Trading
- CHECKPOINT
CHECKPOINT
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Rubra Medicaments do?
Rubra Medicaments Ltd, established in 1991, is engaged in the non-specialized wholesale trade, focusing on traded goods.
Who are the competitors of Rubra Medicaments?
Rubra Medicaments major competitors are NMS Global, IMEC Services, Sirohia & Sons, Nyssa Corporation, Shree Ganesh Elasto, Rama Petrochem., Amforge Inds.. Market Cap of Rubra Medicaments is ₹13 Crs. While the median market cap of its peers are ₹12 Crs.
Is Rubra Medicaments financially stable compared to its competitors?
Rubra Medicaments seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Rubra Medicaments pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Rubra Medicaments latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Rubra Medicaments allocated its funds?
Companies resources are allocated to majorly unproductive assets like Accounts Receivable
How strong is Rubra Medicaments balance sheet?
Balance sheet of Rubra Medicaments is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Rubra Medicaments improving?
The profit is oscillating. The profit of Rubra Medicaments is ₹0.03 Crs for Mar 2024, -₹0.08 Crs for Mar 2023 and -₹0.04 Crs for Mar 2022
Is the debt of Rubra Medicaments increasing or decreasing?
The debt of Rubra Medicaments is decreasing. Latest debt of Rubra Medicaments is -₹0.04 Crs as of Sep-24. This is less than Mar-24 when it was -₹0.03 Crs.
Is Rubra Medicaments stock expensive?
Rubra Medicaments is not expensive. Latest PE of Rubra Medicaments is 0.0, while 3 year average PE is 44.39. Also latest EV/EBITDA of Rubra Medicaments is 0.0 while 3yr average is 43.86.
Has the share price of Rubra Medicaments grown faster than its competition?
Rubra Medicaments has given better returns compared to its competitors. Rubra Medicaments has grown at ~21.73% over the last 10yrs while peers have grown at a median rate of 3.74%
Is the promoter bullish about Rubra Medicaments?
There is Insufficient data to gauge this.
Are mutual funds buying/selling Rubra Medicaments?
There is Insufficient data to gauge this.